Sun Pharma Advanced Research (SPARC) witnessed a rise in share price on Wednesday after it announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for ELEPSIA XR (Levetiracetam extended-release tablets 1000 mg and 1500 mg). ELE PSIA XR is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy.

Shares of the company are trading at Rs 438.50, up Rs 26.75, or 6.50% at the Bombay Stock Exchange (BSE) on Wednesday at 12:26 p.m.

The scrip has touched an intra-day high of Rs 444.90 and low of Rs 406.05. The total volume of shares traded at the BSE is 970,997.